HPV Infection
Conditions
Brief summary
Cervical cancer is due to a persistent infection with a group of viruses known as high-risk Human Papillomaviruses (hrHPV). Viral DNA can be easily detected in a cervical sample by a procedure called 'HPV testing', which can be used as a relevant screening test. A pilot screening program called START-HPV has been set up in the Ardennes, a French administrative area localized in the North of France, with HPV testing as a primary screening test.This observational study aimed to evaluate hrHPV genotypes repartition in the population who participate in the START-HPV screening program. This study will allow a better knowledge of hrHPV infection epidemiology in a screened population.
Interventions
BIOLOGICALHuman papillomavirus genotyping
Sponsors
CHU de Reims
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
31 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* to live in the Ardennes department (France) * affiliation to a health insurance organism * 31 to 65 years old
Exclusion criteria
* current follow-up for cervical cytological abnormalities * history of hysterectomy * reimbursement for a Pap smear in the last 3 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HPV genotyping | Day 0 | DNA extraction from cervical smears (DNAPap Cervical Sampler device, Qiagen) or from self-collected vaginal lavages (Delphi-screener device, DelphiBioscience) and HPV genotyping with the Multiplex HPV Genotyping kit© (Multimetrix, Progen) based on a Luminex technology |
Countries
France
Outcome results
None listed